Published in Women's Health Weekly, January 8th, 2004
Under the terms of the agreement, Teva will receive exclusive marketing rights in the U.S. and Canada to Andrx's line of generic oral contraceptive products currently pending regulatory approval. Andrx will be responsible for all formulations, U.S. regulatory submissions, and manufacturing of products covered under the agreement. Financial terms were not disclosed.
The agreement also provides Teva with an option to acquire similar...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly